Risk of hepatitis B reactivation is controllable in patients with B‐cell lymphoma receiving anti‐CD19 CAR T cell therapy
- DOI
- 10.1111/bjh.16951
- Published
- 2020-07-15
- Container
- British Journal of Haematology
- Publisher
- Wiley
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1111/bjh.16951,
title = {Risk of hepatitis B reactivation is controllable in patients with B‐cell lymphoma receiving anti‐CD19 CAR T cell therapy},
author = {Wei Liu and Wenyang Huang and Min Wang and Rui Lv and Jian Li and Ying Wang and Shuhui Deng and Shuhua Yi and Hong Liu and Qing Rao and Yingxi Xu and Lulu Lv and Lugui Qiu and Dehui Zou and Jianxiang Wang},
year = {2020},
journal = {British Journal of Haematology},
doi = {10.1111/bjh.16951},
url = {https://doi.org/10.1111/bjh.16951}
}RIS
TY - JOUR TI - Risk of hepatitis B reactivation is controllable in patients with B‐cell lymphoma receiving anti‐CD19 CAR T cell therapy AU - Wei Liu AU - Wenyang Huang AU - Min Wang AU - Rui Lv AU - Jian Li AU - Ying Wang AU - Shuhui Deng AU - Shuhua Yi AU - Hong Liu AU - Qing Rao AU - Yingxi Xu AU - Lulu Lv AU - Lugui Qiu AU - Dehui Zou AU - Jianxiang Wang PY - 2020 JO - British Journal of Haematology DO - 10.1111/bjh.16951 UR - https://doi.org/10.1111/bjh.16951 ER -
APA
Liu, W., Huang, W., Wang, M., Lv, R., Li, J., Wang, Y., Deng, S., Yi, S., Liu, H., Rao, Q., Xu, Y., Lv, L., Qiu, L., Zou, D., & Wang, J. (2020). Risk of hepatitis B reactivation is controllable in patients with B‐cell lymphoma receiving anti‐CD19 CAR T cell therapy. British Journal of Haematology. https://doi.org/10.1111/bjh.16951
Source records
- crossref · retrieved 2026-09-26T13:43:37.033Z